An evaluation of compliance of Mass Drug Administration (MDA) against Lymphatic Filariasis of Satna district of Madhya Pradesh, India

Trivedi Rohit

Abstract


Introduction

Mass drug administration (MDA) means once-in-a-year administration of Diethyl Carbamazine (DEC) tablet to all people (excluding children under 2 years, pregnant women and severely ill persons) in identified endemic areas. It aims at cessation of transmission of Lymphatic Filariasis. To study the coverage and compliance of MDA in Satna district during the campaign in June 2013.


Methods

Cross-sectional observational study. Setting: Urban And Rural Areas In Satna District Identified As Endemic For Filariasis Where MDA 2013 Was Undertaken. Study Variables: Exploratory - Rural and urban clusters of Satna district; Outcome - coverage, compliance, actual coverage, side effects.


Results

Four clusters, each comprising 30 households from the Satna endemic district, yielded an eligible population of 650 (95.87%) of total 678. The coverage was 586 (90.15% out of eligible population) with variation across different areas. The compliance with drug ingestion was 88.05% with a gap of 11.95% to be targeted by intensive IEC. The effective coverage (79.38%) was below the target (85%). Side effects of DEC were minimum, transient and drug-specific.


Conclusions

Overall coverage was marginally better in rural areas. The causes of poor coverage and compliance have been discussed and relevant suggestions have been made.


Keywords


Diethyl Carbamazine - MDA - Lymphatic Filariasis.

Full Text:

PDF

References


Bhaskar C, Harinath, Reddy MV. Filariasis in India. J Int Sci Acad 2000; 13:8-12.

WHO. Lymphatic filariasis: Progress of disability prevention activities. Wkly Epidemiol Rec 2004; 7 9:417-24.

Zagaria N, Savioli L. Elimination of lymphatic filariasis: A public-health challenge. Ann Trop Med Parasitol 2002;96: S3-13.

Government of India. Operational guidelines on elimination of lymphatic filariasis. Directorate NVBDCP, 22 Shamnath Marg, Delhi 110054; 2005.

Molyneux DH, Zagaria N. Lymphatic filariasis elimination: Progress in global program development. Ann Trop Med Parasitol 2002;96 Suppl 2: S15-40.

Molyneux D. Lymphatic Filariasis (Elephantiasis) elimination: A public health success and development opportunity. Filaria J 2003;2:13.

Ramaiah KD, Vijay Kumar KN, Chandrakala AV, Augustin DJ, Appavoo NC, Das PK. Effectiveness of community and health services-organized drug delivery strategies for elimination of lymphatic filariasis in rural areas of Tamil Nadu, India. Trop Med Int Health 2001;6:1062-9.

Government of India. National Health Policy. New Delhi: Department of Health, Ministry of Health and Family Welfare; 2002.

Imonsen PE, Meyrowitsch DW, Mukoko DA, Pedersen EM, Malecela-Lazaro MN, Rwegoshora RT, et al. The effect of repeated half-yearly diethylcarbamazine mass treatment on wuchereria bancrofti infection and transmission in two east African communities with different levels of endemicity. Am J Trop Med Hyg 2004;70:63-71.

Ravish KS, Ranganath TS, Riyaz Basha S. Coverage and Compliance of Mass Drug Administration for Elimination of Lymphatic Filariasis in Endemic Areas of Bijapur district, Karnataka. Int J Basic Med Sci 2012;3 81-86.

Kumar P,. Evaluation of MDA 2006 in Gujarat. IJCM 2008;33:38-42.

Babu BV, Satyanarayana K. Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari district, South India. Trop Doct 2003;33:79-82.

Patel PK. Mass drug administration coverage evaluation survey for lymphatic filariasis in Bagalkot and Gulbarga districts. Indian J Community Med 2012;37:101-6.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 Trivedi Rohit

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.